Adjuvant dabrafenib and trametinib improve survival in stage III melanoma
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival compared to placebo in ...
Tag: dabrafenib
#VisualAbstract: Adjuvant Dabrafenib plus Trametinib Improves Outcomes in Stage III Melanoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Circulating tumor DNA levels may predict treatment response in patients with advanced melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma
Click to read the study in Nature Communications
Combination trametinib and dabrafenib show fewer side effects for metastatic melanoma than dabrafenib alone
1. In patients undergoing treatment for metastatic melanoma, there was a statistically significant decreased risk of cutaneous toxic effects in ...